Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430846
Status:
COMPLETED
Last Update Posted:
2014-12-18
First Post:
2007-02-01
Brief Title:
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Study Overview
Official Title:
A Phase I Dose Escalation Study of SGN-35 in Patients With RelapsedRefractory CD30-Positive Hematologic Malignancies
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsedrefractory CD30-positive hematologic malignancies This is a single-arm open-label Phase I dose escalation study designed to define the MTD PK immunogenicity and anti-tumor activity of SGN-35 in patients with relapsedrefractory CD30-positive hematologic malignancies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None